Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

2.790 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 106
Open 2.790
Bid (Size) 2.740 (1)
Ask (Size) 3.290 (1)
Prev. Close 2.790
Today's Range 2.790 - 2.790
52wk Range 2.345 - 16.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire

Performance

YTD
-24.4%
-24.4%
1 Month
-16.5%
-16.5%
3 Month
-30.8%
-30.8%
6 Month
-66.2%
-66.2%
1 Year
-81.8%
-81.8%

More News

Read More
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
Via Benzinga
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
From Biomea Fusion, Inc.
Via GlobeNewswire
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
From Biomea Fusion, Inc.
Via GlobeNewswire
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
Via Benzinga
Exposures Product Safety

Frequently Asked Questions

Is Biomea Fusion, Inc. - Common Stock publicly traded?
Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.
What exchange does Biomea Fusion, Inc. - Common Stock trade on?
Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?
The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market
What is the current price of Biomea Fusion, Inc. - Common Stock?
The current price of Biomea Fusion, Inc. - Common Stock is 2.790
When was Biomea Fusion, Inc. - Common Stock last traded?
The last trade of Biomea Fusion, Inc. - Common Stock was at 03/24/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.